Roche discovered breakthrough therapy Susvimo™ (ranibizumab injection) for the treatment of people with neovascular or ‘wet’ age-related macular degeneration (nAMD).
Susvimoearlier known as port delivery system with ranibizumab is the first and only alternative treatment in 15 years which provides standard-of-care eye injections which requires often in a month.
Susvimo is delivered to eye through refillable implant. The implant is inserted into the eye during a one-time, outpatient procedure and refilled every six months. It helps people with nAMDto maintain their vision as few as two treatments per year. It provides as an alternative to anti-VEGF eye injections by delivering susvimocontinuously.
With the advancements in treatment, Susvimo plays as a new treatment option for patients with wet AMD.
U.S. Food and Drug Administration (FDA) approves Susvimo™, as a first-of-its-kind therapeutic approach for neovascular or ‘wet’ age-related macular degeneration (nAMD).
